ArticlePilot and feasibility studies2025
A community pharmacy-based program to enhance adherence to adjuvant endocrine therapy among breast cancer survivors (PACHA): protocol for a pilot cluster-randomized controlled trial.
Article in Pilot and feasibility studies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05887102 (Pilot Study of a Community Pharmacy-Based Program to Enhance Adherence to Adjuvant Endocrine Therapy Among Breast Cancer Survivors), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pilot Study of a Community Pharmacy-Based Program to Enhance Adherence to Adjuvant Endocrine Therapy Among Breast Cancer Survivors
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundAdjuvant endocrine therapy (AET) is an oral treatment prescribed for 5 to 10 years to women with hormone-sensitive breast cancer. Despite the benefits of AET for reducing breast cancer recurrence, suboptimal adherence is common. Community pharmacists can play a role in supporting women with this treatment, given their frequent encounters with patients, access to refill information, and expertise in managing side effects. The goal of this pilot study is to assess the acceptability and feasibility of implementation, and preliminary effects of the PACHA program, a community pharmacy-based program designed to support women who are prescribed AET. Another goal is to assess the feasibility of a large-scale randomized controlled trial (RCT).
methodsThis is a pilot cluster-RCT using mixed-methods. A cluster consists of a pharmacy, its pharmacists, and its patients with an AET prescription in the last 30 months. Pharmacies will be recruited through targeted advertisement. Participating pharmacies will be randomized 1:1 to two groups (n = 33 pharmacies per group). In the first group (control), pharmacists will provide usual services to women. In the second group (intervention), pharmacists will complete web-based training and perform consultations using a standardized guide based on motivational interviewing principles and evidence-based online strategy sheets to cope with AET side effects. Women in the intervention group will have access to a website featuring video modules on AET, strategies for managing side effects, testimonials from women who have had an AET, and a list of resources. Acceptability and feasibility indicators, as well as psychosocial factors expected to influence AET adherence and treatment experience, will be collected at baseline, during, and at the end of the 6-month follow-up using online questionnaires, study data logs, and pharmacy claim records. Semi-structured interviews will be conducted to explore participants' experiences with the program. DISCUSSION: Results will help to refine the program and, if the results support this, to design a full-scale cluster-RCT to assess the program's effect on 5-year adherence and costs. If effective, this program could fill a gap in breast cancer supportive care and contribute to reducing cancer burden by improving survivorship experience and survival.
trial registrationThis trial has been approved by the Research Ethics Board of the CHU de Québec-Université Laval (MP-20-2023-6625) and registered at Clinicaltrials.gov (NCT05887102) on 2023-05-24, https://classic. CLINICALTRIALS: gov/ct2/show/NCT05887102 , prior to beginning the study. Protocol version 1 is dated as 2022-12-12.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.